search
Back to results

The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit

Primary Purpose

Asthma, Seasonal Allergic Rhinitis

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
exposure to grass pollen/starch granules
Sponsored by
Fraunhofer-Institute of Toxicology and Experimental Medicine
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Asthma

Eligibility Criteria

18 Years - 55 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: • Male and female subjects, aged 18-55 years. Women will be considered for inclusion if they are: Not pregnant or nursing. Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and have been amenorrhoeic for more than 1 year prior to the screening visit). Of childbearing potential and using an appropriate method of contraception (Oral contraceptive pill or double barrier). Documented history of bronchial asthma first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta2-agonist therapy by inhalation. Patients on low dose steroids will be washed out for 4 weeks. FEV1 > 80% of predicted at screening. They have history of allergic rhinitis to grass pollen and a positive skin prick test for Dactylus glomerata pollen at or within 12 months prior to the screening visit. Documented sensitivity to AMP with a provocative concentration of AMP resulting in a 20% fall in FEV1 (PC20 AMP) of <80mg/ml at the screening visit. Non smoker or smokers with a history of less than 10 pack years. Able and willing to give written informed consent to take part in the study. Available to complete all study measurements. Exclusion Criteria: • History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the informed consent and during the study. Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures. Administration of oral, injectable or dermal corticosteroids within 8 weeks or intranasal and/or inhaled corticosteroids within 4 weeks of the screening visit. Administration of xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates and/or long acting beta-agonists within 1 week of the screening visit. Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDS), anti-depressant drugs, anti-histamines and anti-asthma, anti-rhinitis or hay fever medication (other than short acting inhaled beta-agonists) and paracetamol (up to 1g paracetamol per day is permitted for the treatment of minor ailments e.g. headache) for 1 week prior to screening and throughout the course of the study. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis). History of MI or CVA are specific contra-indications to AHR testing Known or suspected hypersensitivity or adverse reaction to AMP Subject is undergoing allergen desensitisation therapy There is a risk of non-compliance with study procedures Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment

Sites / Locations

  • Fraunhofer ITEM

Outcomes

Primary Outcome Measures

AMP hyperrespnsiveness

Secondary Outcome Measures

exhaled NO
FEV1
Rhinomanometry

Full Information

First Posted
September 13, 2005
Last Updated
February 13, 2017
Sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT00209365
Brief Title
The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit
Study Type
Interventional

2. Study Status

Record Verification Date
February 2017
Overall Recruitment Status
Completed
Study Start Date
September 2005 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
December 2005 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Fraunhofer-Institute of Toxicology and Experimental Medicine

4. Oversight

5. Study Description

Brief Summary
The aim of the study is to explore the contribution of pollen starch granules to the induced symptoms and airway inflammation in patients with allergic rhinitis and mild asthma in a controlled pollen exposure(pollen challenge room at the Fraunhofer ITEM). Starch granules are released from the pollen grains and are considered to be the allergen carriers of the pollen. The hypothesis is proposed that pollen starch granules are important in the induction of airway inflammation and airway hyperresponsiveness.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma, Seasonal Allergic Rhinitis

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Double
Allocation
Randomized
Enrollment
24 (false)

8. Arms, Groups, and Interventions

Intervention Type
Procedure
Intervention Name(s)
exposure to grass pollen/starch granules
Primary Outcome Measure Information:
Title
AMP hyperrespnsiveness
Secondary Outcome Measure Information:
Title
exhaled NO
Title
FEV1
Title
Rhinomanometry

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: • Male and female subjects, aged 18-55 years. Women will be considered for inclusion if they are: Not pregnant or nursing. Of non-child bearing potential (i.e. physiologically incapable of becoming pregnant, including any female who is pre-menarchial or post-menopausal with documented proof of hysterectomy or tubal ligation, or meet clinical criteria for menopause and have been amenorrhoeic for more than 1 year prior to the screening visit). Of childbearing potential and using an appropriate method of contraception (Oral contraceptive pill or double barrier). Documented history of bronchial asthma first diagnosed at least 6 months prior to the screening visit and currently being treated only with intermittent short-acting beta2-agonist therapy by inhalation. Patients on low dose steroids will be washed out for 4 weeks. FEV1 > 80% of predicted at screening. They have history of allergic rhinitis to grass pollen and a positive skin prick test for Dactylus glomerata pollen at or within 12 months prior to the screening visit. Documented sensitivity to AMP with a provocative concentration of AMP resulting in a 20% fall in FEV1 (PC20 AMP) of <80mg/ml at the screening visit. Non smoker or smokers with a history of less than 10 pack years. Able and willing to give written informed consent to take part in the study. Available to complete all study measurements. Exclusion Criteria: • History of a respiratory tract infection and/or exacerbation of asthma within 4 weeks before the informed consent and during the study. Any history of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnoea, respiratory arrest or hypoxic seizures. Administration of oral, injectable or dermal corticosteroids within 8 weeks or intranasal and/or inhaled corticosteroids within 4 weeks of the screening visit. Administration of xanthines (including theophylline, but not including caffeine), anticholinergics, cromoglycates and/or long acting beta-agonists within 1 week of the screening visit. Unable to abstain from other medications including non-steroidal anti-inflammatory drugs (NSAIDS), anti-depressant drugs, anti-histamines and anti-asthma, anti-rhinitis or hay fever medication (other than short acting inhaled beta-agonists) and paracetamol (up to 1g paracetamol per day is permitted for the treatment of minor ailments e.g. headache) for 1 week prior to screening and throughout the course of the study. Past or present disease, which as judged by the investigator, may affect the outcome of this study. These diseases include, but are not limited to, cardiovascular disease, malignancy, hepatic disease, renal disease, haematological disease, neurological disease, endocrine disease or pulmonary disease (including but not confined to chronic bronchitis, emphysema, tuberculosis, bronchiectasis or cystic fibrosis). History of MI or CVA are specific contra-indications to AHR testing Known or suspected hypersensitivity or adverse reaction to AMP Subject is undergoing allergen desensitisation therapy There is a risk of non-compliance with study procedures Neurological or psychiatric disease or history of drug or alcohol abuse which would interfere with the subject's proper completion of the protocol assignment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Norbert Krug, MD
Organizational Affiliation
Fraunhofer ITEM
Official's Role
Principal Investigator
Facility Information:
Facility Name
Fraunhofer ITEM
City
Hannover
ZIP/Postal Code
30625
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

The Role of Pollen Starch Granules in Pollen Challenge Studies in the Fraunhofer Environmental Exposure Unit

We'll reach out to this number within 24 hrs